Clinical Trial Update: Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating DA-EPOCH chemotherapy with or without Rituximab plus recombinant Erwinia asparaginase (JZP458) for newly diagnosed Philadelphi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Etoposide (Etoposide)
• PREDNISONE (Prednisone)
• Recombinant Erwinia asparaginase (JZP458) (asparaginase (Erwinia) JZP458)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: University of Washington | Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Status: RECRUITING